Thormbozytenaggregation, Physiologie und pharmakologische Beeinflussung

E. Walter; Ellen Weber

doi:10.1055/s-0038-1656594

Hämostaseologie, Inhaltsverzeichnis

Hamostaseologie 1981; 01(03): 73-86
DOI: 10.1055/s-0038-1656594

Originalarbeiten

Schattauer GmbH

Thormbozytenaggregation, Physiologie und pharmakologische Beeinflussung

E. Walter

¹Abteilung für Klinische Pharmakologie (Direktorin: Prof. Dr. Ellen Weber) der Medizinischen Universitätsklinik Heidelberg

,

Ellen Weber

¹Abteilung für Klinische Pharmakologie (Direktorin: Prof. Dr. Ellen Weber) der Medizinischen Universitätsklinik Heidelberg

› Institutsangaben

Abstract

Zusammenfassung

Um die Basis zu legen für die Darstellung der pharmakologischen Beeinflussung der Thrombozytenfunktion, wird ein kurzer aktueller Überblick gegeben über die Entwicklung der Thrombozyten, ihre Morphologie mit Bezug auf die Funktion und die biochemischen Vorgänge bei der Thrombozytenadhäsion und -aggregation. Soweit bekannt, wird die Wirkung der einzelnen Pharmaka im molekularen und funktionellen Bereich dargestellt, und zwar mit weitestgehender Begrenzung auf die beim Menschen nachgewiesenen Wirkungen. Damit wurde gezielt aus der Fülle der untersuchten Substanzen eine Auswahl getroffen zugunsten von Pharmaka, die auch therapeutisch und nicht nur zur Abklärung von Funktionsmechanismen genutzt werden können. Das Aufzeigen des Wirkungsprofils der Medikamente erleichtert ihren gezielten Einsatz. Dosierungsprobleme werden diskutiert.

Volltext

Referenzen

LITERATUR
1 Adler J. R, Handin R. I. Solubilization and characterization of a platelet membrane ADP-binding protein. J. biol. Chem 1979; 254: 3866-3872.
2 Aharony D, Smith J. B, Smith E. F, Lefer A. M, Magolda R. L, Nicolaon K. D. Pina-ne Thromboxane A₂:A TXA₂ antagonist with antithrombotic properties. In: Samuels-son B, Ramwell P. W, Paoletti R. (Hrsg.): Advances in Prostaglandin und Thromboxane Research. Vol. 6 Raven Press; New York: 1980: 489-492.
3 Alexander R. W, Cooper B, Handin R. I. Characterization of the human platelet al-pha-adrenergic receptor. J. clin. Invest 1978; 61: 1136-1144.
4 Ali M, McDonald J. W. D. Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin. J. Lab. clin. Med 1977; 89: 868-875.
5 Ali M, McDonald J. W. D. Interference by sulfinpyrazone and salicylate of aspirin inhibition of platelet cyclooxygenase activity. Prostagl. Med 1979; 3: 327-332.
6 Andrassy K, Ritz E, Hasper M, Scherz E, Walter E, Storch H, Völmel W. Penicillin-induced coagulation disorder. Lancet II: 1039-1041. 1976;
7 Andrassy K, Zimmermann R, Höffler D, Ritz E, Scherz M. Plättchenfunktionsstörung -eine Carbenicillin-Nebenwirkung bei normaler Nierenfunktion. Klin. Wschr 1977; 55: 1021-1023.
8 Amezcua J. L, Parson M, Moncada S. Unstable metabolites of arachidonic acid, aspirin and the formation of the haemostatic plug. Thromb. Res 1978; 13: 477-488.
9 Ardlie N. G, Glew G, Schwartz C. J. Influence of catecholamines on nucleotide-induced platelet aggregation. Nature 1966; 212: 415-416.
10 Ashida S. J, Abiko Y. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat. Thrombos. Haemostas 1979; 41: 436-449.
11 Ashida S, Sakuraa K, Abiko Y. Antithrombotic effects of ticlopidine, acetyl-salicylic acid and dipyridamol in vascular shunt model in rats. Tbrorab. Res 1980; 17: 663-671.
12 Atac A, Spagnuolo M, Zucker M. B. Long-term inhibition of platelet functions by aspirin. Proc. Soc. eip. Biol 1970; 133: 1331-1333.
13 Aursnes I, Gjesdal K, Abildgaard U. Platelet aggregation induced by ADP from unsheared erythrocytes at physiological Ca⁺⁺-concentrations. Brit. J. Haemat 1981; 47: 149-152.
14 Awbrey B. J, Hoak J. C, Owen W. G. Binding of human thrombin to cultured endothelial cells. J. biol. Chem 1979; 254: 4092-4095.
15 Baenzinger N. L, Dillender M. J, Majerus P. Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandin. Biochem. biophys. Res. Commun 1977; 78: 294-301.
16 Balleisen L, Gay S, Marx R, Kühn K. Comparative investigation on the influence of human and bovine collagen types I. II and III on the aggregation of human platelets. Klin. Wschr 1975; 53: 903-905.
17 Balleisen L, Nowak H, Gay S, Timpl R. Inhibition of Collagen-induced platelet aggregation by antibodies to distinct types of collagen. Biochem. J 1979; 184: 683-687.
18 Balleisen L. J, Rauterberg J. Platelet activation by basement membrane collagens. Thromb. Res 1980; 18: 725-732.
19 Barber A. J, Jamieson G. A. Isolation and characterization of plasma membranes from human platelets. J. biol. Chem 1970; 245: 6359-6365.
20 Barber A. J, Jamieson G. A. Platelet-collagen adhesion: Characterization of collagen gluco-syltransferase of plasma membranes of human blood platelets. Biochim. biophys. Acta 1971; 252: 533-545.
21 Barnes M. J, Bailey A. J, Gordon J. L, Maclntyre D. E. Platelet aggregation by basement membrane-associated collagens. Thromb. Res 1980; 18: 375-388.
22 Barnhart M. I. Platelet responses in health and disease. Mol. Cell. Biochem 1978; 22: 113-137.
23 Basista M, Dobranowski J, Gryglewski R. Prostacyclin and thromboiane generating systems in rabbits pretreated with aspirin. Pharmacol Res. Commun 1978; 10: 759-763.
24 Baumgartner H. R. Effects of acetylsalicylic acid, sulfinpyrazone and dipyridamole on platelet adhesion and aggregation in flowing native and anticoagulated blood. Haemostasia 1979; 8: 340-352.
25 Bauvois B, Legrand C, Caen J. P. Interaction of adenosine and adenylnucleotides with the human platelet membrane. Further characterization of the ADP-binding sites, Haemostasia 1980; 9: 92-104.
26 Beaumont J. L, Willie A, Lenègre J. Influence de l’acide acétyl-salicylique sur l’hémostase. Bull Soc, Méd, Hop. Paris 1955; 71: 1077-1087. a
27 Beaumont J. L, Caen J, Bernard J. Action hémorragipare de l’acide acétyl-salicylifueau cours des maladies du sang. Bull. Soc. Méd. Hop. Paris 1955; b 71: 1087-1092.
28 Behnke O. Microtubules in disk-shaped blood ceis. Int. Rev. Exp. Pathol 1970; 9: 1-92.
29 Bell R. L, Kennedy D. A, Stanford N, Majerus P. W. Diglyceride lipase: A pathway for arachidonate release from human platelets. Proc. Natl Acad. Sci. USA 1979; 76: 3238-3241.
30 Bell R. L, Stanford N, Kennerly D. A, Majerus P. W. Diglyceride lipase: A pathway for arachidonate release from human platelets. In: Samuelsson B, Ramwell P. W, Paoietti R. (Hrsg.): Advances in Prostaglyndin and Thromboxane Research. Vol.6 Raven Press; New York: 1980: 219-224.
31 Bell R. L, Majerus P. W. Thrombin-induced hydrolysis of phosphatidyl inositol in human platelets. J. biol. Chem 1980; 255: 1790-1792.
32 Bennett J. S, Colman R. F, Colman R. W. Identification of adenine nucleotide binding proteins in human platelet membranes by affinity labelling with 5’-p-fluorosulfonyl-benzoyl adenosine. J. biol. Chem 1978; 253: 7346-7354.
33 Bennett J. S, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J. clin. Invest 1979; 64: 1393-1401.
34 Bensusan H. B, Koh T. L, Henry K. G, Murray B. A, Culp L. A. Evidence that fibronec-tin is the collagen receptor on platelet membranes. Proc. Natl. Acad. Sci. (USA) 1978; 75: 5864-5868.
35 Bereziat G. Are phospholipases involved in platelet activation?. Agents and Actions 1979; 9: 390-399.
36 Bills T. K, Smith J. B, Silver M. J. Selective release of arachidonic acid from the phospholipids in response to thrombin. J. clin. Invest 1977; 60: 1-6.
37 Blatrix Ch. Allongement du temps de saignement sous l’influence de certain médicaments. Nouv. Rev. Franc. Hemat 1963; 3: 346-350.
38 Bolhuis P. A, Sakariassen K. S, Sixma J. J. Adhesion of blood platelets to human arterial subendothelium: role of factor VIII - von Willebrand. factor. Haemostasis 1979; 8: 312-323.
39 Boneu B, Sie P, Caranobe C, Nouvel C, Bierme R. Malondialdehyde (MDA) reappearance in human platelet density subpopulations after a single intake of aspirin. .Thromb. Res 1980; 19: 609-620.
40 Bonne C, Martin B, Watada M, Regnault F. The antagonism of prostaglandins I₂ E₁ and D₂ by prostaglandin E₂ in human platelets. Thromb. Res 1981; 21: 13-22. a
41 Bonne C, Martin B, Regnault F. Hypothetic mechanism of ticlopidine-induced hypersensitivity to PGEj in rat platelets. Thromb. Res 1981; b 21: 157-164.
42 Born G. V. R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929.
43 Born G. V. R, Cross M. Y. The aggregation of platelets. J. Physiol 1963; 168: 178-195.
44 Bowie E. J. W, Owen C. A. The bleeding time. In: Spaet T. H. (ed.) Progress in Hemostasia and Thrombosis Grane and Stratton Inc.; New York: 1974: 249-271.
45 Bressler N. M, Broekman M. J, Marcus A. J. Current studies of oiygen consumption and aggregation in stimulated human platelets. Blood 1979; 53: 167-178.
46 Broekman M. J, Ward J. W, Marcus A. J. Phospholipid metabolism in stimulated human platelets. Changes in phosphatidyl inositol, phosphatidic acid and lysophospholipids. J. clin. Invest 1980; 66: 275-283.
47 Brown C. H, Natelson E. A, Bradshaw W, Williams T. W, Alfrey C. P. The hemostatic defect produced by carbenicillin. New Engl. J. Med 1974; 291: 265-270.
48 Brune K, Glatt M, Kahn H, Peskar B. A. Pharmacological control of prostaglandin and thromboxane release from macrophages. Nature (Lond.) 1978; 274: 261-263.
49 Buchanan M. P, Rosenfeld R, Hirsh J. The prolonged effect of sulfinpyrazone on collagen-induced platelet aggregation in vivo. Thromb. Res 1979; 13: 883-892.
50 Burch J. W, Stanford N, Majerus P. W. Inhibition of platelet prostaglandin synthetase by oral aspirin. J. clin. Invest 1978; 61: 314-319. a
51 Burch J. W, Baenzinger N. L, Stanford N, Majerus P. W. Sensitivity of fatty acid cyclo-oxygenase from human aorta to acetylation by aspirin. Proc. Natl Acad. Sci. (USA) 1978; b 75: 5181-5184.
52 Burch J. W, Majerus P. W. The role of prostaglandins in platelet function. Seminars in Hematology 1979; 16: 196-207.
53 Burns J. J, Yu T. F, Ritterband A, Perel J. M, Gutman A. B, Brodie B. B. A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G. 25 671. J. Pharmacol exp. Ther 1957; 119: 418-426.
54 Bye A, Lewis Y, O’Grady J. Effect of a single oral dose of aspirin on the platelet aggregation response to arachidonic acid. Brit. J. clin. Pharmacol 1979; 7: 283-286.
55 Caen J. P. Blood platelet function. Nouv. Rev. Fr. Hématol 1979; 21: 81-89.
56 Carter A. E, Eban R, Perrett R. D. Prevention of postoperative deep venous thrombosis and pulmonary embolism. Brit. Med. J 1971; 1: 312-314.
57 Carter A. E, Eban R. Prevention of postoperative deep venous thrombosis in legs by orally administered hydroxychloroquine sulfate. Brit. med. J 1974; 3: 94-95.
58 Carvalho A. C. A, Colman R. W, Less R. S. Clofibrate reversal of platelet hypersensitivity in hyperbetalipoproteinemia. Circulation 1974; 50: 570-574.
59 Cerskus A. L, Ali M, McDonald J. W. D. Thromboxane B₂ and 6-keto-prostaglandin F_lA synthesis during infusion of collagen and arachidonic acid in rabbits: Inhibition by aspirin and sulfinpyrazone. Thromb. Res 1980; 18: 693-705.
60 Chap H. J, Zwall R. F. A, Van Deenan L. L. M. Action of highly purified phospholipases on blood platelets: evidence for an asymmetric distribution of phospholipids in the surface membrane. Biochim. biophys. Acta 1977; 467: 146-164.
61 Chignard M, Le Couedic J. P, Tencé M, Vargaftig B. B, Benveniste J. The role of platelet-activating factor in platelet aggregation. Nature 1979; 179: 799-800.
62 Chignard M, Le Couedic J. P, Vargaftig B. B, Benveniste J. Platelet-activating factor (PAF-Acether) secretion from platelets: Effects of aggregating agents. Brit. J. Haemat 1980; 46: 455-464.
63 Chierchia S, Ciabattoni G, Cinotti G, Maseri A, Patrono C, Pulgiese F, Distante A, Simonetti I, Bernini W. Haemodynamic and antiaggregatory effects of prostacyclin (PGI₂) in healthy man. Circulation 59 + 60 Suppl.II 1979; 83
64 Cho M. J, Allen M. A. Chemical stability of prostacyclin in aequous solution. Prostaglandins 1978; 15: 943-954.
65 Clemetson K. J, Capitanio A, Lüscher E. F. High resolution two dimensional gel electrophoresis of the protein and glycoproteins of human blood platelets and platelet membranes. Biochim. biophys. Acta 1979; 553: 11-24.
66 Cooper D. R, Lewis G. P, Lieberman G. E, Webb H, Westwick J. ADP metabolism in vascular tissue, a possible thrombo-regulato-ry mechanism. Thromb. Res 1979; 14: 901-914.
67 Coppe D, Wonders Th, Snider M, Salzman E. W. Preservation of platelet number and function during extracorporeal oxygenation by regional infusion of prostacyclin. In: Vane J. R, Bergström S. (Hrsg.): Prostacyclin Raven Press; New York: 1979: 371-384.
68 Cusack N. J, Hickman M. E, Born G. V. R. Effects of D- and L-enantiomers of adenosine. AMP and ADP and their 2-chloro- and 2-azido-analogues on human platelets. Proc. R. Soc. Lond. B 1979; 206: 139-144.
69 Czervionke R. L, Smith J. B, Fry G. L, Hoak J. C. Inhibition of prostacyclin by treatment of endothelium with aspirin. J. clin. Invest 1979; 63: 1089-1092.
70 Davey M. G, Lüscher E. F. Actions of some coagulant snake venoms on blood platelets. Nature (Lond.) 1965; 207: 730-732.
71 David J. L, Monfort F, Herion F, Raskinet H. R. Compared effects of three dose-levels of ticlopidine on platelet function in normal subjects. Thromb. Res 1979; 14: 35-49.
72 Davison E. M, Ford-Hutchinson A. W, Smith M. J. H, Walker J. R. The release of thromboxane B₂ by rabbit peritoneal polymorph nuclear leukocytes. Brit. J. Pharmacol 63: 407P 1978;
73 Demers L. M, Budin R. E, Shaikh B. The effects of aspirin on megakaryocyte prostaglandin production. Proc. Soc. exp. Biol 1980; 163: 24-29.
74 Demopoulos C. A, Pinckard R. N, Hanahan D. J. Platelet-activating factor. Evidence for l-0-alkyl-2-acetyl-sn-glyceryl-3-pho-sphorylcholine as the active component (a new class of lipid chemical mediators). J. biol. Chem 1979; 254: 9355-9358.
75 Derksen A, Cohen P. Patterns of fatty acid release from endogenous substrates by human platelet homogenates and membranes. J. biol. Chem 1975; 250: 9342-9347.
76 Dieterle W, Faigle J. W, Moppert J. New metabolites of sulfinpyrazone in man. Drug. Res 30 (01) 989-993. 1980;
77 Di Minno G, Silver M. J, De Gaetano G. Ingestion of dipyridamole reduces inhibitory effect of prostacyclin on human platelets. Lancet II: 701-702. 1979;
78 Dusting G. J, Moncada S, Vane J. R. Disappearance of prostacyclin in the circulation of the dog. Brit. J. Pharmacol 1977; 62: 514-515.
79 Dybdahl J. H, Daae L. N. W, Eika C, Godai H. C, Larsen S. Acetylsalicylic acid-induced prolongation of bleeding time in healthy men. Scand. J. Haematol 1981; 26: 50-56.
80 Dyerberg J, Bang H. O. Haemostatic function and platelet polyunsaturated fatty acids in eskimos. Lancet II: II: 433-435. 1979;
81 Ebihara A, Aoki N, Yoshida N, Sano M, Matsubayashi K, Suzuki T. Clinical pharmacology of a new antithrombotic agent, ticlopidine. Jap. J. Clin. Pharmacol 1978; 9: 395-402.
82 Ellis D. J, Bruno J. J, Roe R. L, Cranston B, Chang R. N, Chang L. F. Effects of ticlopidine hydrochloride, a new antithrombotic drug, on bleeding time and platelet function in man. Clin. Pharmacol. Ther 1981; 29: 243
83 Elwood P. C, Cochrane A. L, Burr M. L, Sweetnam P. M, Williams G, Welsby E, Hughes S. J, Renton R. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Brit. med. J I: 436-440. 1974;
84 Elwood P. C, Sweetnam P. M. Aspirin and secondary mortality after myocardial infarction. Lancet II: 1313-1315. 1979;
85 Evans G, Packham M. A, Nishizawa E. E, Mustard J. F, Murphy E. A. The effect of acetylsalicylic acid on platelet function. J. exp. Med 1968; 128: 877-894.
86 Fitzgerald G. A, Friedman L. A, Miyamori I, O’Grady J, Lewis P. J. A double blind placebo controlled cross-over study of prostacyclin in man. Life Sci 1979; 25: 665-672.
87 Frishman W. H, Weksler B, Christodou-lou J. P, Smithen C, Killip T. Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris. Circulation 1974; 50: 887-898.
88 Fucella L. M, Corvi G, Moro E, Pogliani E, Tamassia V, Tosolini G. Pharmacokinetic, bioavaiability and pharmacodynamic study of indobufen (K 3920), an inhibitor of platelet aggregation, after a single dose in man. Europ. J. clin. Pharmacol 1979; 15: 323-327.
89 Fukami M. H, Holmsen H, Bauer J. Throm-bin-induced oxygen consumption, malondial-dehyde formation and serotonin secretion in human platelets. Biochim. biophys. Acta 1976; 428: 253-256.
90 Fukami M. H, Salganicoff L. Human platelet storage organelles. Thrombos. Haemostas. (Stuttg.) 1977; 38: 963-970.
91 Ganguly P. Binding of thrombin to functionally defective platelets: a hypothesis on the nature of the thrombin receptor. Brit. J. Haemat 1977; 37: 47-51.
92 Gast L. F. Influence of aspirin on haemostatic parameters. Ann. rheum. Dis 1964; 23: 500-504.
93 Gerrard J. M, Townsend D, Stoddard S, Witkop C. J, White J. G. The influence of Prostaglandine G₂ on platelet ultrastructure and platelet secretion. Amer. J. Pathol 86 (01) 99-115. 1977;
94 Girolami A, Celia G, Dal Bo Zanon R, Capellato M. G, Randi M. L. Aspirin and bleeding time. Lancet II: 205-206. 1979;
95 Godal H. C, Eika C, Dybdahl J. H, Daae L, Larsen S. Aspirin and bleeding time. Lancet I 1979; 1236
96 Goldstein J. M, Malmsten C. L, Kin-dahl H. K, Kaplan H. B, Radmark O, Samu-elsson B, Weissman G. Thromboxane generation by human peripheral blood polymorph-nuclear leukocytes. J. exp. Med 1978; 148: 787-792.
97 Gordon J. L, Pearson J. D. Effects of sulfinpyrazone and aspirin on prostaglandin I₂(prostacyclin) synthesis by endothelial cells. Brit. J. Pharmacol 1978; 64: 481-483.
98 Gorman R. R. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors. In: Samuelsson B, Ram-well P. W, Paoletti R. (Hrsg.): Advances in Prostaglandin and Thromboxane Research. Vol.6 Raven Press; New York: 1980: 417-425.
99 Grant J. A, Scrutton M. C. Novel alpha₂-adrenoceptors primarily responsible for inducing human platelet aggregation. Nature 1979; 277: 659-661.
100 Green D, Dunne B, Schmid F. R, Rossi E. C, Lons G. A study of the variable response of human platelets to collagen: Relation to aspirin-induced inhibition of aggregation. Amer. J. clin. Path 1973; 60: 920-926.
101 Gupta K. C, Paul T, Manikeri S, Kulkarni V. N, Pispati P. K, Sheth U. K. Effect of three dosage schedules of flurbiprofen on platelet function and coagulation. Indian. J. Med. Res 1980; 72: 434-440.
102 Hagen I, Nurden A, Bjerrum O. J, Solum N. O, Caen J. Immuno-chemical evidence for protein abnormalities in platelets with Glanzmann’s thrombasthenia and Bernard-Soulier syndrome. J. clin. Invest 1980; 65: 722-731.
103 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically activ compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA 1975; 72: 2994-2998.
104 Hangarter W. Die Salicylsäure und ihre Abkömmlinge. Ursprung, Wirkung und Anwendung in der Medizin. VII. Wirkung auf das Blut Schattauer; Stuttgart -New York: 1974: 187-248.
105 Harker L. A, Slichter S. J. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. New Engl. J. Med 1970; 283: 1302-1305.
106 Harker L. A, Slichter S. J. The bleeding time as a screening test for evaluation of platetet function. New Engl. J. Med 1972; 287: 155-159. a
107 Harker L. A, Slichter S. J. Platelet and fibrinogen consumption in man. New Engl. J. Med 1972; b 287: 999-1005.
108 Harker L. A, Slichter S. J. Arterial and venous thromboembolism: Kinetic characterization and evaluation of therapy. Thrombos. Haemostas. (Stuttg.) 1974; 31: 188-203.
109 Harker L. A, Slichter S. J, Scott C. R, Ross R. Homocystinemia. Vascular injury and arterial thrombosis. New Engl. J. Med 1974; 291: 537-543.
110 Harker L. A, Hazzard W. Platelet kinetic studies in patients with hyperlipoproteinemia: effects of Clofibrate therapy. Circulation 1979; 60: 492-496.
111 Harris D. N, Asaad M. M, Phillips M. B, Goldenberg H. J, Antonaccio M. J. Inhibition of adenylate cyclase in human blood platelets by 9-substituted adenine derivatives. J. Cyclic. Nucl. Res 5 (02) 125-134. 1979; a
112 Harris R. H, Ramwell P. W, Gilmer P. J. Cellular mechanisms of prostaglandin action. Ann. Rev. Physiol 1979; b 41: 653-688.
113 Haslam R. J, Lynham J. A, Fox J. E. B. Effects of collagen, ionophore A 2. 3187 and prostaglandin E₁ on the phosphorylation of specific proteins in blood platelets. Biochem. J 1979; 178: 397-406.
114 Hathaway D. R, Adelstein R. S. Human platelet myosin light chain kinase requires the calcium binding protein calmodulin for activity. Proc. Natl. Acad. Sci 1979; 76: 1653-1657.
115 Heinrich D. Immunreaktionen mit menschlichen Plättchen: Bemerkungen zur Pathogenese. Diagnostik und klinischen Relevanz In: Breddin K. (Hrsg.): Prostaglandine und Plättchenfunktion Schattauer; Stuttgart - New York: 1978: 3-16.
116 Heptinstall S, Bevan J, Cockbill S. R, Hanley S. P, Parry M. J. Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb. Res 1980; 20: 219-230.
117 Higgs G. A, Bunting S, Moncada S, Vane J. R. Polymorphnuclear leukocytes produce thromboxane A₂-like activity during phagocytosis. Prostaglandins 1976; 12: 749-757.
118 Hoak J. C, Czervionke R. L, Fry G. L, Smith J. B. Interaction of thrombin and platelets with the vascular endothelium. Federation Proc 1980; 39: 2606-2609.
119 Holmsen H. Biochemistry of the platelet release reaction. In: Biochemistry and Pharmacology of Blood Platelets Elsevier, Exerpta Medica; North Holland, Amsterdam: 1975: 175-205.
120 Holmsen H. Prostaglandin endoperoxide-thromboxane synthesis and dense granule secretion as positive feedback loops in the propagation of platelet responses during »The Basic Platelet Reaction«. Thrombos. Haemostas. (Stuttg.) 1977; 38: 1030-1041.
121 Holmsen H, Weiss H. J. Secretable storage pools in platelets. Ann. Rev. Med 1979; 30: 119-134.
122 Hsu C. Y, Knapp D. R, Halushka P. The effects of alpha adrenergic agents on human platelet aggregation. J. Pharmacol. exp. Ther 1979; 208: 366-370.
123 Jaffe E. A, Weksler B. B. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. J. clin. Invest 1979; 63: 532-535.
124 Jakobs K. H, Saur W, Schultz G. Reduction of adenylate cyclase activity in lysates of human platelets by the alpha-adrenergic component of epinephrine. J. Cycl. Nucl. Res 1976; 2: 381-392.
125 Jakobs K. H, Saur W, Schultz G. Characterization of the alpha-and beta-adrenergic receptors linked to human platelet adenylate cyclase. Naunyn-Schmiedeberg’s Arch. Pharmacol 1978; 302: 285-291.
126 Jakobs K. H, Saur W, Johnson R. A. Regulation of platelet adencylate cyclase by adenosine. Biochim. biophys. Acta 1979; 583: 409-421.
127 Jamieson G. A, Urban C. L, Barber A. J. Enzymatic basis for platelet-collagen adhesion as a primary step in hemostasis. Nature (New Biol.) 1971; 234: 5-7.
128 Jamieson G. A, Okumura T, Fishback B, Johnson M. M, Egan J. J, Weiss H. J. Platelet membrane glycoproteins in thrombasthenia. Bernard-Soulier Syndrome, and storage pool disease. J. Lab. clin. Med 1979; 93: 652-660. a
129 Jamieson G. A, Okumura T, Hasitz M. Structure and function of platelet glycocali-cin. Thrombos. Haemostas. (Stuttg.) 1979; b 42: 1673-1678.
130 Johnson S. A. Platelets in hemostasis and thrombosis. In: Johnson S. A. (Hrsg.): The Circulating Platelet Academic Press; New York – London: 1971: 356-394.
131 Jorgensen K. A, Dyerberg J, Schou Olesen A, Stoffersen E. Acetylsalicylic acid, bleeding time and age. Thromb. Res 1980; 19: 799-805.
132 Kannagi R, Koizumi K. Effect of different physical states of phospholipid substrates on partially purified platelet phospholipase A₂activity. Biochim. biophys. Acta 1979; 556: 423-433.
133 Kao K. J, Pizzo S. U, McKee P. A. Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets. J. clin. Invest 1979; 63: 656-664.
134 Kaplan L, Weiss J, Elsbach P. Low concentrations of indomethacin inhibit phospholipase A₂ of rabbit polymorphnuclear leukocytes. Proc. Natl. Acad. Sci. (USA) 1978; 75: 2955-2958.
135 Karpatkin S. Heterogeneity of human platelets. I. Metabolic and kinetic evidence suggestive of young and old platelets. J. clin. Invest 1969; 48: 1073-1082.
136 Karpatkin S. Heterogeneity of Rabbit Plate-lets. VI. Further resolution of changes in platelet density, volume, and radioactivity following cohort labelling with, ⁷⁵Se-Seleno-methione. Brit. J. Haemat 1978; 39: 459-469.
137 Kelly W. N. Effects of drugs on uric acid in man. Ann. Rev. Pharmacol 1975; 15: 327-350.
138 Kelton J. G, Hirsh J, Carter C. J, Buchanan M. R. Thrombogenic effect of high-dose of aspirin in rabbits; relationship to inhibition of vessel wall synthesis of prostaglandin I₂like activity. J. clin. Invest 1978; 62: 892-895.
139 Kirby E. P. Factor VIII-associated platelet aggregation. Thrombos. Haemostas. (Stuttg.) 1977; 38: 1054-1072.
140 Kirchmaier C. H, Gran Rheinfelder B, Rüfer A, Trautmann O, Sehrbrock M, Breddin K. Zur Hemmung von ASS und Dipy-ridamol auf die Stimulation der Thrombozyten. In: Deutsch E, Lechner K. (Hrsg.): Fibrinolyse, Thrombose, Haemostase Schattauer; Stuttgart - New York: 1980: 759-763.
141 Kirstein-Pedersen A, Jakobsen P. Two new metabolites of sulfinpyrazone in the rabbit: A possible cause of the prolonged in vivo effect. Thrombos. Haemostas 1979; 16: 871-876.
142 Kirstein P, Jogestrand T, Johnsson H, Olsson A. G. Antiaggregatory, physiological and clinical effects of ticlopidine in subjects with peripheral atherosclerosis. Atherosclerosis 1980; 36: 471-480.
143 Knudsen J. B, Gormsen J. The effect of ticlopidine on platelet function in normal volunteers and in patients with platelet hyperaggregability in vitro. Thromb. Res 1979; 16: 663-671.
144 Köttgen E, Bauer Ch, Reutter W, Gerok W. Neue Ergebnisse zur biologischen und medizinischen Bedeutung von Glycoproteinen. I. Grundlagen und interdisziplinäre Ge sichtspunkte. Klin. Wschr 1979; 57: 151-159. a
145 Köttgen E, Bauer Ch, Reutter W, Gerok W. Neue Ergebnisse zur biologischen und medizinischen Bedeutung von Glycoproteinen. II. Ausgewählte klinische Fachgebiete. Klin. Wschr 1979; b 57: 199-214.
146 Kohler C, Tolman E, Wooding W, Ellenbogen L. Fenbufen and biphenylacetic acid inhibit platelet function and the arachodinate prostaglandin system. Thromb. Res 1980; 20: 123-135.
147 Korbut R, Moneada S. Prostacyclin (PGI₂) and thromboxane A₂ interaction in vivo. Regulation by aspirin and relationship with antithrombotic therapy. Thromb. Res 1978; 13: 489-500.
148 Kronick P, Jimenez S. A. The size of collagen fibrils that stimulate platelet aggregation in human plasma. Biochem. J 1980; 186: 5-12.
149 Lacombe M. J, Varet B, Godeau P, Her-reman G, Cenac A. Action de fortes doses de pénicillin G sur les plaquettes. Nouv. Presse Med 1974; 3: 1435-1437.
150 Le Breton G. C, Venton D. L. Thromboxane A₂ receptor antagonism selectively reverses platelet aggregation. In: Samuelsson B, Ramwell P. W, Paoletti R. (Hrsg.): Advances in Prostaglandin and Thromboxane Research. Vol.6 Raven Press; New York: 1980: 497-503.
151 Lecrubier C, Conard J, Samara M, Bousser M. G. Essai randomisé d’un nouvel agent anti-aggrégant: La ticlopidine. Thérapie 1977; 32: 189-194.
152 Lin C. Y, Smith S. The effect of halofenate and Clofibrate on aggregation and release of serotonin by human platelets. Life Sci 1976; 18: 563-568.
153 Lips J. P. M, Sixma J. J, Tieschnigg A. C. Inhibition of uptake of adenosine into human blood platelets. Biochem. Pharmacol 1980; 29: 43-50.
154 Livio M, Villa S, De Gaetano G. Long-lasting inhibition of platelet prostaglandin but normal vascular prostacyclin generation following sulphinpyrazon administration to rats. J. Pharm. Pharmacol 1980; 32: 718
155 Loiseau P. Sodium valproate, platelet dysfunction and bleeding. Epilepsia 1981; 22: 141-146.
156 Longmore D. B, Bennett G, Gueirrara D, Smith M, Bunting S, Reed P, Moncada S, Read N. G, Vane J. R. Prostacyclin: A solution to some problems of extracorporeal circulation. Lancet I: 1002-1005. 1979;
157 Lüscher E. F, Massini P. Common pathways of membran reactivity after stimulation of platelet by different agents. In: Biochemistry and Pharmacology of Platelets Elsevier, Excerpta Medica; North-Holland, Amsterdam, Oxford, New York: 1975: 5-21.
158 Lüscher E. F. New insights into the structure and function of platelet merribrans. In: Mills D. C. B, Pareti F. I. (Hrsg.): Platelets and Thrombosis Academic Press; London, New York: 1977: 1-8.
159 Maguire E. D, Pay G. F, Turney J, Wallis R. B, Weston M. J, White A. M. C, Williams L, Woods H. F. The effect of two different dosage regimens of sulfinpyrazone on platelet function ex vivo and blood chemistry in man. Haemostasis 1981; 10: 153-164.
160 Mant M. J. Platelet adherence to collagen: metabolic energy requirements. Thromb. Res 1980; 77: 729-736.
161 Marcus A. J, Ullman H. L, Safier L. B. Lipid composition of subcellular particles of human blood platelets. J. Lipid Res 1969; 10: 108-114.
162 Margulies E. H, White A. M, Sherry S. Sulfinpyrazone: A review of its pharmacological properties and therapeutic use. Drugs 1980; 20: 179-197.
163 Masotti G, Poggesi L, Galanti G, Abbate R, Neri Serneri G. G. Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet II: II: 1213-1216. 1979; a
164 Masotti G, Poggesi L, Galanti G, Neri Serneri G. G. Stimulation of prostacyclin by dipyridamole. Lancet I 1979; b 1412
165 Masotti G, Poggesi L, Galanti G, Neri Serneri G. G. Increase of circulating PGI₂ and PGI₂ released by vessel wall after dipyridamole. Thrombos. Haemostas 1979; c 42: 197
166 Massini P. The role of calcium in the stimulation of platelets. In: Mills D. C. B, Pareti F. I. (Hrsg.): Platelets and Thrombosis Academic Press; London, New York: 1977: 33-43.
167 Mauco G, Chap H. J, Douste-Blazy L. Characterization and properties of a phosphatidylinositol phosphodiesterase (phospholipase C) from platelet cytosol. FEBS Lett 1979; 100: 367-370.
168 McElroy F. A, Philp R. B. Relative potencies of dipyridamole and related agents as inhibitors of cyclic nucleotide phosphodiesterases: possible explanation of mechanism of inhibition of platelet function. Life Sci 1974; 17: 1479-1494.
169 Mclntyre D. E. Modulation of platelet function by prostaglandins: Characterization of platelet receptors for stimulatory prostaglandins and the role of arachidonate metabolites in platelet degranulation responses. Haemostasis 1979; 8: 274-293.
170 Mclntyre B. A, Philp R. B. The effects of four platelet inhibitors on human platelets using two adhesiveness test systems. Canad. J. Physiol. Pharmacol 1980; 58: 699-705.
171 Mellwig K. P, Jakobs K. H. Inhibition of platelet adenylate cyclase by ADP. Thromb. Res 1980; 18: 7-17.
172 Menche D, Israel A, Karpatkin S. Platelets and Microtubules. Effect of colchicin and D ₂O on platelet aggregation and release induced by calcium ionophore A 23187. J. clin. Invest 1980; 66: 284-291.
173 Merino X, Livio M, Rajtar G, De Gaetano G. Salycylate reverses in vitro aspirin inhibition of rat platelet and vascular prostaglandin generation. Biochem. Pharmacol 1980; 29: 1093-1096.
174 Mielke C. H, Ramos J. C, Britten A. F. H. Aspirin as an antiplatelet agent: template bleeding time as a monitor of therapy. Amer. J. clin. Path 1973; 59: 236-242.
175 Mills D. C. B, Roberts G. C. K. Effects of adrenaline on human blood platelets. J. Physiol. (Lond.) 1967; 193: 443-453.
176 Mills D. C. B, Smith J. B. The influence of platelet aggregation of drugs that effect the accumulation of adenosine 3’:5’-cyclic monophosphate in platelets. Biochem. J 1971; 121: 185-196.
177 Moneada S, Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet II: 1286-1289. 1978;
178 Moneada S, Vane J. R. Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Brit. med. Bull 1978; 34: 129-135.
179 Moneada S, Vane J. R. The pharmacology and clinical potential of prostacyclin. In: Turner P. (ed.): Clinical Pharmacology and Therapeutics S. Macmillan Publishers; London and Basingstoke: 1980
180 Moore A, Ross G, Nachman R. L. Interaction of platelet membrane receptors with von Willebrand factor, ristocetin, and the Fc region of immunoglobulin G. J. clin. Invest 1978; 62: 1053-1060.
181 Morgenstern E, Walter E, Weber E. Functional aspects of lysosomal organelles in blood platelets. Z. Zeilforsch 1971; 118: 283-296.
182 Mürer E. H. Release reaction and energy metabolism in blood platelets with special reference to the burst on oxygen uptake. Biochim. biophys. Acta 1968; 162: 320-326.
183 Mustard J. F, Rowsell H. C, Smythe H. A, Senyi A, Murphy E. A. The effect of sulfinpyrazone on platelet economy and thrombus formation in rabbits. Blood 1967; 29: 859-866.
184 Nachman R. L, Ferris B. Binding of adenosine diphosphate by isolated membranes from human platelets. J. biol. Chem 1974; 249: 704-710.
185 Nachman R. L, Jaffe E. A. Subcellular platelet factor VIII antigen and von Willebrand factor. J. exp. Med 1975; 141: 1101-1113.
186 Nachmias V. T. Cytoskeleton of human plate-lets at rest and after spreading. J. cell. Biol 1980; 86: 795-802.
187 Nadell J, Bruno J, Varady J, Segre E. J. Effect of naproxen and of aspirin on bleeding time in platelet aggregation. J. clin. Pharmacol 1974; 14: 176-182.
188 Natelson E. A, Siebert W. T, Williams T. W, Bradshew M. W. Combined effect of ticar-cillin and cefazolin on blood coagulation and platelet function. Amer. J. med. Sci 278 (03) 217-221. 1979;
189 Needleman P, Moneada S, Bunting S, Vane J. R, Hamberg M, Samuelsson B. Indenti-fication of an enzyme in platelet microsomes which generates thromboxane A₂ from prostaglandin endoperoxides. Nature 1976; 261: 558-560.
190 Needleman P, Wyche A, Raz A. Platelet and blood vessel arachidonate metabolism and interactions. J. clin. Invest 1979; 63: 345-349.
191 Nenci G. G, Agnelli G, Berrettini M, Parise P, Ballatori E. Inhibition of spontaneous platelet aggregation by sulfinpyrazone. Thrombos. Haemostas. (Stuttg.) 1979; 42: 621-625.
192 Neri Serneri G. G, Masotti G, Poggesi L, Galanti G. Dipyridamole stimulates prostacyclin biosynthesis in man and in vitro. World Congress of Angiology, Sept Abstr.227. Athen 1980: 7-12.
193 Niewiarowski S. Proteins secreted by the platelet. Thrombos. Haemostas. (Stuttg.) 1977; 38: 924-938.
194 Nunn B. Collagen-induced platelet aggregation. Evidence against the essential role of platelet adenosine diphosphate. Thrombos. Haemostas. (Stuttg.) 1979; 42: 1193-1206.
195 Nunn B, James F. Effect of sulphinpyrazone on human platelet aggregation. 5-hydroxy-tryptamine release and adhesion ex vivo: comparison with naproxen. Brit. J. clin. Pharmacol 1980; 9: 239-245.
196 Nurden A. T, Caen J. P. Membrane glycoproteins and human platelet function. Brit. J. Haemat 1978; 38: 155-160.
197 Nurden A. T, Horisberger M, Savarian E, Caen J. P. Visualisation of lectin binding sites on the surface of human platelets using lectins adsorbed to gold granules. Experien-tia 1980; 36: 1215-1217.
198 O’Brien J. R. Effects of salicylates on human platelets. Lancet I: 779-783. 1968;
199 O’Brien J. R, Etherington M. D, Shuttleworth R. D. Ticlopidine - an antiplatelet drug: effects in human volunteers. Thromb. Res 1978; 13: 245-254.
200 O’Grady J, Moneada S. Aspirin: a paradoxical effect on bleeding-time. Lancet II 1978; 780
201 O’Grady J, Warrington S, Moti M. J, Bunting S, Flower R, Fowle A. S. E, Higgs E. A, Moneada S. Effects of intravenous prostacyclin infusions in healthy volunteers -some preliminary observations. In: Vane J. R, Bergström S. (Hrsg.): Prostacyclin. S Raven Press; New York: 1979: 409-417.
202 Packham M. A, Mustard J. F. The effect of pyrazole compounds on thrombin-induced platelet aggregation. Proc. Soc. exp. Biol 1969; 130: 72-75.
203 Packham M. A, Mustard J. F. Non-steroidal anti-inflammatory drugs, pyrimido-pyrimi-dine compounds and tricyclic compounds. Effects on platelet function. In: Hirsh J, Cade J. F, Gallus A. S, Schönborn E. (Hrsg.): Platelets, Drugs and Thrombosis. S. Karger, Basel, München; Paris, London, New York, Sidney: 1975: 111-123.
204 Packham M. A, Mustard J. F. Clinical pharmacology of platelets. Blood 1977; 50: 555-573.
205 Paterson A. R. P, Lau E. Y, Dahlig E, Cass C. E. A common basis for inhibition of nucleoside transport by dipyridamole and nitrobenzylthioinosine? Mol. Pharmacol 1980; 18: 40-44.
206 Paulus J. M, Bury J, Grosdent J. C. Control of platelet territory development in megakaryocytes. Blood Cells 1979; 5: 59-88.
207 Pay G. F, Wallis R. B, Zelaschi D. The effect of sulphinpyrazone and its metabolites on platelet function in vitro and ex vivo. Haemostasis 1981; 10: 165-175.
208 Penington D. G, Lee N. L. Y, Roxburgh A. E, McGready J. R. Platelet density and size: The interpretation of heterogeneity. Brit. J. Haemat 1976; 34: 365-376.
209 Penny R, Rozenberg M. C, Firkin B. G. The splenic platelet pool. Blood 1966; 27: 1-16.
210 Pepper D. S. Macromolecules released from platelet storage organelles. Thrombos. Haemostas. (Stuttg.) 1979; 42: 1667-1672.
211 Perrot B, Chap H. J, Douste-Blazy L. Asymmetric distribution of arachidonic acid in the plasma membrane of human platelets. Bio-chim. biophys. Acta 1979; 556: 434-446.
212 Pfister B, Imhof P. Influence of vasodilators used in the therapy of heart failure on platelet aggregation. Agents and Actions 1979; 9: 217-219.
213 Pfister B, Godbillon J, Colussi D, Imhof P. Effect of orally administered sulphinpyrazone (Anturan®) on platelet aggregation in vitro. Thromb. Res 1980; 18: 89-99.
214 Philips D. R. Effect of trypsin on the exposed polypeptides and glycoproteins in the human platelet membrane. Biochemistry 1972; 11: 4582-4588.
215 Phillips D. R, Agin P. P. Platelet plasma membrane glycoproteins, identification of a proteolytic substrate for thrombin. Biochem. biophys. Res. Commun 1977; 75: 940-947. a
216 Phillips D. R, Agin P. P. Platelet plasma membrane glycoproteins. J. biol. Chem 1977; b 252: 2121-2126.
217 Pitney W. R, Nicol M, Dean S, Hickey A. Effect of flurbiprofen on bleeding time and platelet aggregation. Thrombos. Res 1978; 13: 811-819.
218 Polley M. J, Nachman R. L. Human complement in thrombin-mediated platelet function. Uptake of C _5b_₉ complex. J. exp. Med 1979; 150: 633-645.
219 Polonsky J, Tencé M, Varenne P, Das B. C, Lunel J, Benveniste J. Release of 1-0-alkylglyceryl 3-phosphorylcholine. 0-deace-tyl platelet-activating factor, from leucocytes: chemical ionization mass spectrometry of phospholipids. Proc. Natl. Acad. Sci. (USA) 1980; 77: 7019-7023.
220 Prescott S. M, Majeras P. W. The fatty acid composition of phosphatidylinositol from thrombin-stimulated human platelets. J. biol. Chem 1980; 256: 579-582.
221 Ramwell P. General introduction to clinical implications of prostaglandin synthetase-inhibitors. In: Ramwell P. (Hrsg.): Prostaglandin synthetase inhibitors. New clinical applications Alan R. Liss Inc., XI; New York: 1980
222 Rajah S. M, Penny A, Kester R. Aspirin and bleeding-time. Lancet II 1978; 1104
223 Rajah S. M, Penny A. F, Crow M. J, Pepper M. D, Watson D. A. The interaction of varying doses of dipyridamole and acetyl salicylic acid on the inhibition of platelet functions and their effect on bleeding-time. Brit. J. clin. Pharmacol 1979; 8: 484-489.
224 Rittenhouse-Simmons S, Russel F. A, Deyken D. Mobilization of arachidonic acid in human platelets: Kinetics and Ca⁺⁺ dependency. Biochem. biophys. Acta 1977; 488: 370-380.
225 Rittenhouse-Simmons S, Russel F. A, Deykin D. Production of diglyceride from phosphatidylinositol in activated human platelets. J. clin. Invest 1979; 63: 580-587.
226 Rittenhouse-Simmons S. Indomethacin-in-duced accumulation of diglyceride in activated human platelets. The role of diglyceride lipase. J. biol. Chem 1980; 255: 2259-2262.
227 Rossi E. C, Louis G, Zeller E. A. Structure activity relationships between catecholamines and the alpha-adrenergic receptor responsible for the aggregation of human platelet by epinephrine. J. Lab. clin. Med 1978; 93: 286-294.
228 Roth G. J, Majeras P. W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particular fraction protein. J. clin. Invest 1975; 56: 624-632.
229 Roth G. J, Stanford N, Majeras P. W. Acetylation of prostaglandin synthetase by aspirin. Proc. Natl. Acad. Sci 1975; 72: 3073-3076.
230 Roth G. J, Siok C. J. Acetylation of NH₂-terminal serine of prostaglandin synthetase by aspirin. J. biol. Chem 1978; 253: 3782-3784.
231 Rozenberg M. C, Walker C. M. The effect of pyrimidine compounds on the potentiation of adenosine inhibition of aggregation, on adenosine phosphorylation and phosphodiesterase activity of blood platelets. Brit. J. Haemat 1973; 24: 409-418.
232 Russel F. A, Deykin D. The effect of thrombin on the uptake and transformation of arachidonic acid by human platelets. Amer. J. Hematol 1976; 1: 59-70.
233 Sánchez-Crespo M, Alonso F, Egido J. Platelet-activating factor in anaphylaxis and phagocytosis. I. Release from human peripheral polymorphnuclears and monocytes during the stimulation by ionophore A 2. 3187 and phagocytosis but not from degranulating basophils. Immunology 1980; 40: 645-655.
234 Santoro S. A, Cunningham L. W. Collagen-mediated platelet aggregation. Evidence for multivalent interactions of intermediate specificity between collagen and platelets. J. clin. Invest 1977; 60: 1054-1060.
235 Santoro S. A, Cunningham L. W. Fibronectin and multiple interaction model for platelet-collagen adhesion. Proc. Natl. Acad. Sci. (USA) 1979; 76: 2644-2648.
236 Santoro S. A, Cunningham L. W. Collagen-mediated platelet aggregation: The role of multiple interactions between the platelet surface and collagen. Thrombos. Haemostas 1980; 43: 158-162.
237 Schafer A. I, Cooper B, O’Hara D, Handin R. I. Identification of platelet receptors for prostaglandin I₂ and D₂ . J. biol. Chem 1979; 254: 2914-2917.
238 Scharrer I, Schepping M, Breddin K. Throm-boseprophylaxe mit Aspirin? Der Einfluß von Acetylsalicylsäure auf die Thrombo-cytenaggregation in vitro und in vivo. Klin. Wschr 1969; 47: 1318-1324.
239 Schick P. K, Kurica K. B, Chacko G. K. Location of phosphatidylethanolamine and phosphatidylserine in the human platelet plasma membrane. J. clin. Invest 1976; 57: 1221-1226.
240 Schneider W, Reimers H. J, Morgenstern E. Thrombocytenstoffwechsel. In: Breddin K. (Hrsg.): Prostaglandine und Plättchenfunktion. S. Schattauer; Stuttgart, New York: 1978: 19-35.
241 Schneider W, Morgenstern E. Zellbiologische Grundlagen der Plättchenfunktion. Throm-bos. Haemostas 1981; 44: 1-16.
242 Shattil S. J, Cooper R. A. Membrane micro-viscosity and human platelet function. Biochemistry 1976; 15: 4832-4837.
243 Shattil S. J, Cooper R. A. Role of membrane lipid composition, organization and fluidity in human platelet function. Prog. Hemost. Thromb 1978; 4: 59-86.
244 Shattil S. J, McDonough M, Tumbull J, Insel P. A. Characterization of alpha-adrenergic receptors in human platelets using (³H) Clonidin. Mol. Pharmacol 1980; 19: 179-183. a
245 Shattil S. J, Bennett J. S, McDonough M, Turnbull J. Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface. J. clin. Invest 1980; b 65: 329-337.
246 Shattil S. J, McDonough M, Turnbull J, Insel P. A. Characterization of alpha-adrenergic receptors in human platelets using (³H) Clonidin. Mol. Pharmacol 1981; 19: 179-183.
247 Sidhu P, Sutherland S. B, Ganguly P. Interaction of thrombin with mammalian platelets. Amer. J. Physiol 237 (03) 1979; H 353-H 358.
248 Siess W, Roth P, Weber P. C. Thromboxan (TX)-Bildung und Thrombozytenaggregation in vitro: Messung und möglicher funktioneller Zusammenhang. In: Deutsch E, Lechner K. (Hrsg.): Fibrinolyse, Thrombose, Haemostase. S. Schattauer; Stuttgart, New York: 1980. a 273-275.
249 Siess W, Scherer B, Böhling B, Roth P, Kurzmann I, Weber P. C. Platelet-membrane fatty acids, platelet aggregation and thromboxane formation during a mackerel diet. Lancet 1980; b I: 441-444.
250 Sixma J. J, Lips J. P. N, Trieschnigg A. N. C, Holmsen H. Transport and metabolism of adenosine in human blood platelets. Bio-chim. biophys. Acta 1976; 443: 33-48.
251 Smith J. B, Willis A. L. Aspirin selectively inhibits prostaglandin production in human platelets. Nature New Biol. (Lond.) 1971; 251: 235-237.
252 Smith J. B, Ingerman C, Kocsis J. J, Silver M. J. Formation of prostaglandins during the aggregation of human blood platelets. J. clin. Invest 1973; 52: 965-969.
253 Smith J. B. Prostaglandins, platelet function and thrombosis. In: Breddin, K. (Hrsg.): Prostaglandine und Plättchenfunktion. S. Schattauer; Stuttgart, New York: 1978: 37-51.
254 Smith J. B, Araki H, Lefer A. M. Thromboxane A₂ prostacyclin and aspirin: effects on vascular tone and platelet aggregation. Circulation 62 Suppl.: V 19-V 25. 1980;
255 Smythe H. A, Ogryzlo M. A, Murphy E. A, Mustard J. G. The effect of sulfinpyrazone (Anturan) on platelet economy in man. Canad. med. Ass. J 1965; 92: 818-821.
256 Snyder J. A, Mcintosh J. R. Biochemistry and physiology of microtubules. Ann. Rev. Bio-chem 1976; 45: 677-720.
257 Solum N. O, Hagen I, Peterka M, Gjem-dal T. Absence of the 14 5000 molecular weight, soluble platelet membrane glycoprotein - lack of platelet agglutination. Throm-bos. Haemostas. (Stuttg.) 1979; 42: 1626-1629.
258 Solum N. O, Hagen Ch, Filion-Myklebust I, Stabaek T. Platelet glycocalicin - its membrane association and solubilization in aqueous media. Biochim. biophys. Acta 1980; 597: 235-246.
259 Steele P. P, Battock D, Genton E. Effects of Clofibrate and sulfinpyrazone on platelet survival time in coronary artery disease. Circulation 1975; 52: 473-476.
260 Steele P. Trial of dipyridamole-aspirin in recurrent venous thrombosis. Lancet II: 1328-1329. 1980;
261 Steer M. L, Khorana J, Galgoci B. Quantitation and characterization of human platelet alpha-adrenergic receptors using (³H) Phen-tolamine. Mol. Pharmacol 1979; 16: 719-728.
262 Stuart M. J, Murphy S, Oski F. A, Evans A. E, Donaldson M. H, Garner F. H. Platelet function in recipients of platelets from donors ingesting aspirin. New Engl. J. Med 1972; 287: 1105-1109.
263 Stuart M. J, Murphy S, Oski F. A. A simple nonradioisotope technic for the determination of platelet life-span. New Engl. J. Med 1975; 292: 1310-1313.
264 Subbarao K, Rucinski B, Rausch M. A, Schmid K, Niewiarowski S. Binding of dipyridamole to human platelets and alpha!-acid glycoprotein and its significance for the inhibition of adenosine uptake. J. clin. Invest 1977; 60: 936-943.
265 Szczeklik A, Gryglewski R. J. Actions of prostacyclin in man. In: Vane J. R, Bergström S. (Hrsg.): Prostacyclin. S Raven Press; New York: 1979: 393-407.
266 Tarn S. W, Detwiler T. C. Binding of thrombin to human platelet plasma membranes. Biochim. biophys. Acta 1978; 543: 194-201.
267 Tamassia V, Corvi G, Fucella L. M, Moro E, Tosolini G, Tremoli E. Indobufen (K 3920), a new inhibitor of platelet aggregation: effect of food on bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration to man. Europ. J. clin. Pharmacol 1979; 15: 329-333.
268 Tao R. V. P, Sweeley C. C, Jamieson G. A. Sphingolipid composition of human platelets. J. Lipid Res 1973; 14: 16-25.
269 Tencé M, Polonsky J, Le Couedic J. P, Benveniste J. Release, purification and characterization of platelet-activating factor (PAF). Biochimie 1980; 62: 251-259.
270 Thebault J. J, Lagrue G, Blatrix C. E, Cheynier L, Cluzan R. Clinical pharmacology of flurbiprofen: a novel inhibitor of platelet aggregation. Curr. Med. Res. Op 1977; 5: 130-134.
271 Thomas D. P. The role of platelet catecholamines in the aggregation of platelets by collagen and thrombin. Exp. Biol. Med 1968; 3: 129-133.
272 Tollefsen D. M, Feagler J. R, Majerus P. W. The binding of thrombin to the surface of human platelets. J. biol. Chem 1974; 249: 2646-2651.
273 Tollefsen D. M, Majerus P. W. Evidence for a single class of thrombin-binding sites on human platelets. Biochemistry 1976; 15: 2144-2148.
274 Treacher D, Warlow Ch, McPherson K. Aspirin and bleeding-time. Lancet II 1978; 1378
275 Trugnan G, Bereziat G, Manier M. C, Polonowski J. Phospholipase activities in subcellular fractions of human platelets. Biochim. biophys. Acta 1979; 573: 61-72.
276 Tsai B. S, Lefkowitz R. Multiple effects of guanine nucleotides on human platelet adenylate cyclase. Biochim. biophys. Acta 1979; 587: 28-41.
277 Tschopp T. B, Weiss H. J, Baumgart-ner H. R. Decreased adhesion of platelets to sub-endothelium in von Willebrand’s disease. J. Lab. clin. Med 1974; 83: 296-300.
278 Tyler H. M, Saxton C. A. P. D, Parry M. J. Administration to man of UK-37. 248-01, a selective inhibitor of thromboxane synthetase. Lancet I: 629-632. 1981;
279 Ubatuba F. B, Moncada S, Vane J. R. The effect of prostacyclin (PGI₂) on platelet behavior, thrombus formation in vivo and bleeding time. Thrombos. Haemostas. (Stuttg.) 1979; 47: 425-435.
280 Ulutin O. N. The platelet secretion mechanism in normal and in pathological conditions. J. med. Enzymology 1977; 2: 86-103.
281 Vallee E, Gongat J, Ageron M. Inhibition of platelet phospholipase A₂ as a mechanism for the antiaggregating effect of linoleic acid. Agents and Actions 1980; 10: 57-62.
282 Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature New Biol 1971; 231: 232-235.
283 Vane J. R, Bergström S. Editors of Prostacyclin. S. Raven Press; New York: 1979: 1-453.
284 Vargaftig B. B. Salicylic acid fails to inhibit generation of thromboxane A₂ activity in platelets after in vivo administration to the rat. J. Pharm. Pharmacol 1978; 30: 101-104.
285 Vargaftig B. B, Chignard M, Le Couedic J. P, Benveniste J. One, two, three or more pathways for platelet aggregation. Acta Med. Scand. (Suppl.) 1980; 642: 23-29.
286 Vargaftig B. B, Chignard M, Benveniste J. Present concepts on the mechanism of platelet aggregation. Biochem. Pharmacol 1981; 30: 263-271.
287 Vermylen J, Carreras L. O, Schaeren J. V, Defreyn G, Machin S. J, Verstraete M. Thromboxane synthetase inhibition as antithrombotic strategy. Lancet I: 1073-1075. 1981;
288 Vinazzer H, Fuccella L. M. Clinical pharmacology studies with indobufen (K 3920): inhibitor of platelet aggregation. J. clin. Pharmacol 1980; 20: 316-325.
289 Walenga R, Vanderhoek J. Y, Fein-stein M. B. Serine esterase inhibitors block stimulus-induced mobilization of arachidonic acid and phosphatidylinositide-specific phospholipase C activity in platelets. J. biol. Chem 1980; 255: 6024-6027.
290 Walter E, Weber E. Überwachung der Behandlung mit Aggregationshemmern. Med. Welt 1976; 27: 1369-1371.
291 Walter E, Weber E. Wirkung von Sulfinpyra-zon in vitro auf die gesteigerte Thrombo-cytenaggregation. Drug. Res 28 (02) 1778-1781. 1978; a
292 Walter R, Weber E. Unterschiedliches Langzeitverhalten der Thrombocytenfunktion nach Myocardinfarkt in Abhängigkeit von der verwendeten Testmethode. In: Breddin K. (Hrsg.): Prostaglandine und Plättchenfunktion. S Schattauer; Stuttgart, New York: 1978. b 139-142.
293 Walter E, Hodok-Laibach P, Zimmermann R, Weber E. Action and interaction of sulfinpyrazone in anticoagulated patients. Thrombos. Haemostas. (Stuttg.) 1979; 42: 62 a
294 Walter E, Siess R, Zimmermann R, Weber E. Also high dose of aspirin prolongs bleeding time, but later after ingestion. Thrombos. Haemostas. (Stuttg.) 42 (01) 1979; b 242
295 Walter E, Staiger C, Weber E. Funktion und Interaktion von Sulfinpyrazon bei antikoagu-lierten Patienten. Verh. Dtsch. Ges. Inn. Med 1980; 86: 1253-1256. a
296 Walter E, Zimmermann R, Siess R, Staiger C, Weber E. Biphasic initial phase of platelet aggregation inhibition after oral aspirin. Artery 1980; b 8: 501-506.
297 Walter E, Staiger C, de Vries J, Zimmermann R, Weber E. Induction of drug metabolizing enzymes by sulfinpyrazone. Europ. J. clin. Pharmacol 1981; 19: 353-358. a
298 Walter E, Kohlmeier M, Schlierf G, Weber E. Thrombozytenfunktion nach wiederholter polyensäurereicher Diät und Normalkost bei gesunden Männern. Verh. Dtsch. Ges. Inn. Med. 87 1981. b im Druck.
299 Walter E, Zimmermann R, Lehle R, Weber E. Influence of an orally active thromboxane synthesis inhibitor on platelet function in man. Thrombos. Haemostas 46 (01) 1981; 278 c
300 Wautier J. L, Reid K. B. M, Legrand Y, Caen J. P. Region of the Clq molecule involved in the interaction between platelet and subcomponent Clq of the first component of complement. Mol. Immunology 1980; 17: 1399-1405.
301 Wautier J. L, Legrand Y. J, Fauvel F, Caen J. P. Inhibition of platelet collagen interactions by the Cl s subcomponent of the first component of complement. Thromb. Res 1981; 21: 3-12.
302 Weber E, Walter E, Morgenstern E, Mondt H, Rose U, Towliati H, Knaudt E. Untersuchungen an fraktionierten Plättchen-homogenaten. I. Zur Charakterisierung dreier lysosomaler Enzyme und über die Differenzierung des alpha-Gramilomer. Biochem. Pharmacol 1970; 19: 1893-1912.
303 Weily H. S, Genton E. Altered platelet function in patients with prosthetic mitral valves. Effects of sulfinpyrazone therapy. Circulation 1970; 42: 967-972.
304 Weisschedel E, Andrassy K, Koderisch J, Ritz E. Thrombocytenfunktionsstörung durch PenicilHn-Derivate. Wechselwirkung mit Prostaglandin-Stoffwechsel. In: Fibrinolyse, Thrombose, Hämostase. Eds E. Deutsch, K. Lechner, Schattauer; Stuttgart, New York: 611-614. 1980
305 Weiss H. J, Aledort L. M. Impaired platelet/ connective tissue reaction in man after aspirin ingestion. Lancet II: 495-497. 1967;
306 Weiss H. J, Rogers J. Fibrinogen and platelets in the primary arrest of bleeding. New Engl. J. Med 1971; 285: 369-374.
307 Weiss H. J, Hoyer L. W, Rickles F. R, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand’s disease that is necessary for platelet aggregation: relationship to factor VIII procoagulant activity and antigen content. J. clin. Invest 1973; 52: 2708-2716.
308 Weiss H. J, Turitto V. T, Baumgartner H. R. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. 1. Shear rate-dependent decrease of adhesion in von Willebrand’s disease and the Bernard-Soulier Syndrome. J. Lab. clin. Med 1978; 92: 750-764.
309 Weksler B. B, Gillick M, Pink J. Effect of propranolol on platelet function. Blood 1977; 49: 185-196.
310 White J. G. Platelet morphology. In: Johnson S. A. (Hrsg.): The Circulating Platelet. S Academic Press; New York, London: 1971: 46-122.
311 White J. G, Gerrard J. M. Platelet morphology and the ultrastructure of regulatory mechanisms involved in platelet activation. In: de Gaetano G, Garattini S. (Hrsg.): Plate-lets: A Multidisciplinary Approach. S Raven Press; New York: 1978: 17-34.
312 White J. G. Current concepts of platelet structure. Amer. J. clin. Path 1979; 71: 363-378.
313 Workman E. F, White G. C, Lundblad R. L. Structure-function relationships in the interaction of alpha-thrombin with blood platelets. J. biol. Chem 1977; 252: 7118-7128.
314 Zimmermann R, Hoffrichter A, Walter E, Ehlers W, Andrassy K, Lang P. D, Schlierf G, Weber E, Barth P. Orale Antikoagulation and Thrombocytenfunktion bei hypolipämischer Behandlung mit einem neuen Clofi-brat-Analog (BM 15. 075). Dtsch. med. Wschr 1977; 102: 509-512.
315 Zimmermann R, Thiessen M, Walter E, Mörl H. Paradoxical effect of high and low dose aspirin in experimental arterial thrombosis. Artery 8 (05) 422-425. 1980;
316 Zucker M. B, Broekman M. J, Kaplan K. L. Factor Vlll-related antigen in human blood platelets. Localization and release by thrombin and collagen. J. Lab. clin. Med 1979; 94: 675-682. a
317 Zucker M. B, Mosesson M. W, Broekman M. J, Kaplan K. L. Release of platelet fibri-nonectin (Cold-insuluble globulin) from alpha granules induced by thrombin or collagen; lack of requirement for plasma fibro-nectin in ADP-induced platelet aggregation. Blood 1979; b 54: 8-12.